Inova Translational Medicine Institute | GenomeWeb

Inova Translational Medicine Institute

Inova plans to offer broad and condition-specific PGx gene panels in its specialty clinics and is negotiating with payors for reimbursement. 

Inova is using Translational's platform to evaluate data from MediMap, a new test that evaluates pharmacogenetics markers in seven genes in newborns.

At Inova Women's Hospital, all new parents have the chance to have pharmacogenetic testing for their babies with the results stored in the electronic medical record.  

Thirteen institutions and life sciences companies have teamed up to launch the free repository that will offer access to allele frequency information from genomes and exomes.

Inova will use GenoSpace's solution to analyze clinical and genomic data from an ongoing whole-genome sequencing initiative.

The Inova Translational Medicine Institute has been exploring the diagnostic use of whole-genome sequencing in newborns with unexplained syndromes in a research setting and plans to transition to a clinical diagnostic test by the end of this year.

This article has been updated to reflect the increased size of a study by Inova.

NEW YORK (GenomeWeb News) – The Inova Translational Medicine Institute and GNS Healthcare today announced a deal to develop and commercialize computer models based on GNS' technology.

By Monica Heger
The market for whole human genome sequencing is shifting from the research sector to the clinic, Complete Genomics's CEO said at the Morgan Stanley Global Healthcare conference last week.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.